Cancer clinical trials in the region Bourgogne-Franche-Comté

127 currently recruiting clinical trials
Region Bourgogne-Franche-Comté

Early Access Lung cancer
NSCLC (Non-Small Cell Lung Cancer) Locally Advanced Metastatic EGFR Targeted therapy
Systemic Treatment-Naive
6 main criterias to confirm
Janssen
Early Access Lung cancer
NSCLC (Non-Small Cell Lung Cancer) Locally Advanced Metastatic EGFR None Systemic Treatment-Naive
7 main criterias to confirm
Janssen
Early Access Lung cancer
NSCLC (Non-Small Cell Lung Cancer) Non-squamous NSCLC Locally Advanced EGFR None Chemotherapy Radiotherapy
8 main criterias to confirm
AstraZeneca
Early Access Lung cancer
NSCLC (Non-Small Cell Lung Cancer) Localized ALK None Systemic Treatment-Naive Surgery
8 main criterias to confirm
Hoffmann-La Roche
Early Access Lung cancer
NSCLC (Non-Small Cell Lung Cancer) Localized PDL1 Positive (1% <= X < 25%) PDL1 Positive (25% <= X < 50%) PDL1 Positive (>= 50%) None Systemic Treatment-Naive
ALK EGFR
8 main criterias to confirm
Bristol-Myers Squibb
Early Access Lung cancer
SCLC (Small Cell Lung Cancer) Localized Locally Advanced None Chemotherapy Radiotherapy Chemotherapy Radiotherapy
7 main criterias to confirm
AstraZeneca
Phase 3 Kidney cancer
#NCT06364631
Clear cell carcinoma Metastatic None 0 1 or 2 Systemic Treatment-Naive
7 main criterias to confirm
CGFL Dijon - Centre Régional De Lutte Contre Le Cancer Georges - François Leclerc (Dijon ), Centre Hospitalier Universitaire de Besançon (Besançon)
Gustave Roussy, Campus du cancer, Grand Paris
Phase 3 Rectal cancer
#NCT06762405
Adenocarcinoma Localized Locally Advanced MSI/dMMR None Systemic Treatment-Naive Systemic Treatment-Naive
Immunotherapy Chemotherapy Radiotherapy Immunotherapy Chemotherapy Radiotherapy
9 main criterias to confirm
Centre hospitalier universitaire François Mitterrand (Dijon)
CHU Dijon
Phase 3 Lung cancer
#NCT06345729
NSCLC (Non-Small Cell Lung Cancer) Metastatic KRAS G12C PDL1 Positive (>= 50%) None Systemic Treatment-Naive
Immunotherapy
9 main criterias to confirm
Centre hospitalier universitaire François Mitterrand (Dijon)
Merck Sharp & Dohme LLC
Phase 3 Lung cancer
#NCT06472245
NSCLC (Non-Small Cell Lung Cancer) Metastatic Other mutation Immunotherapy
ALK EGFR ROS-1
6 main criterias to confirm
Centre Hospitalier Universitaire de Besançon (Besançon)
OSE Immunotherapeutics